This report covers a detailed review of RNA therapeutics for the treatment of cardiovascular, renal, and metabolic indications, highlighting emerging trends, recent advancements, and notable commercial activity
Key highlights include:
- RNA therapeutics now represent a significant and growing share of CVRM pipelines, with over 900 assets targeting cardiovascular, renal, and metabolic indications
- RNAi remains the dominant modality, accounting for over half of CVRM RNA assets and 75% of approved programmes, driven largely by the success of GalNAc‑based hepatic delivery.
- Extra‑hepatic delivery is a major innovation frontier, with recent high‑value deals and platform investments targeting cardiac and muscle tissue beyond the liver.
- Commercial and clinical momentum continues to build, with billion‑dollar partnerships, rapidly expanding mRNA and gene‑editing pipelines, and several late‑stage and first‑in‑class assets to watch in 2026 and beyond.
You May Also Be Interested In…
Learn More About RNA
What is Beacon RNA?
- The Most Comprehensive Way to Search the RNA Drug Development Landscape: Unique search ontologies based on RNA drug and trial characteristics
- Market Leading Approach to RNA Preclinical & Clinical Data Curation: Manual curation of key RNA research and development data points by RNA research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search RNA company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
